Indivior Pharmaceuticals, Inc.
INDVNasdaq
$40.54
↓ -0.1%Jul 17 close · end-of-day
Price
1Y↑ +20.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.2B
Enterprise Value
$5.5B
P/E
20.8
P/S
4.1
P/B
—
EV/EBITDA
16.2
PEG
—
FCF Yield
-3.7%
Dividend Yield
—
Revenue (TTM)
$1.3B
Net Income (TTM)
$252.0M
Free Cash Flow (TTM)
-$192.0M
Gross Margin
81.4%
Operating Margin
25.8%
Net Margin
19.5%
ROE
-175.0%
ROIC
169.7%
Debt / Equity
-3.4
Net Cash
-$311.0M
Return 1Y
—
Company profile
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
- CEO
- Joseph J. Ciaffoni
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 827
- Headquarters
- Virginia
- Website
- www.indivior.com
Management & directors
- Heidbreder ChristianChief Scientific Officer
- Ciaffoni JosephChief Executive Officer
- Preblick RyanChief Financial Officer
- Anderson Woodrow DChief Accounting Officer
- Burris Jeffrey WChief Legal Officer
- Barry Patrick AChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
INDV Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$317.0M↑ +19.2%
Diluted EPS$0.69↑ +81.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $901.0M | $1.1B | $1.2B | $1.2B |
| Gross profit | $749.0M | $919.0M | $957.0M | $994.0M |
| Operating income | -$77.0M | -$152.0M | $38.0M | $262.0M |
| Net income | -$42.0M | -$126.0M | $7.0M | $210.0M |
| Diluted EPS | -$0.30 | -$0.92 | $0.05 | $1.64 |
| Operating cash flow | -$4.0M | -$300.0M | $36.0M | -$27.0M |
| Free cash flow | -$9.0M | -$308.0M | $7.0M | -$93.0M |
| Gross margin | 83.1% | 84.1% | 80.6% | 80.2% |
| Operating margin | -8.5% | -13.9% | 3.2% | 21.1% |
| Net margin | -4.7% | -11.5% | 0.6% | 16.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $299.0M | $307.0M | $298.0M | $266.0M | $302.0M | $314.0M | $357.0M | $317.0M |
| Gross profit | $220.0M | $241.0M | $250.0M | $221.0M | $250.0M | $230.0M | $293.0M | $277.0M |
| Operating income | -$118.0M | $35.0M | $46.0M | $66.0M | $72.0M | $43.0M | $81.0M | $137.0M |
| Net income | -$97.0M | $22.0M | $21.0M | $47.0M | $18.0M | $42.0M | $103.0M | $89.0M |
| Diluted EPS | -$0.72 | $0.16 | $0.16 | $0.38 | $0.14 | $0.33 | $0.79 | $0.69 |
| Operating cash flow | $88.0M | $2.0M | -$17.0M | $75.0M | $158.0M | -$39.0M | -$221.0M | -$9.0M |
| Free cash flow | $84.0M | -$5.0M | -$33.0M | $70.0M | $141.0M | -$59.0M | -$245.0M | -$29.0M |
| Gross margin | 73.6% | 78.5% | 83.9% | 83.1% | 82.8% | 73.2% | 82.1% | 87.4% |
| Operating margin | -39.5% | 11.4% | 15.4% | 24.8% | 23.8% | 13.7% | 22.7% | 43.2% |
| Net margin | -32.4% | 7.2% | 7.0% | 17.7% | 6.0% | 13.4% | 28.9% | 28.1% |
Company news
Jun 29, 2026
Jun 26, 2026
Jun 25, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Heidbreder Christian· Chief Scientific Officer | Sale | 18,586 | $41.14 | $764,628.04 | filing |
| 2026-06-22 | Ciaffoni Joseph· Chief Executive Officer | Tax withholding | 612,549 | $38.32 | $23.5M | filing |
| 2026-06-22 | Ciaffoni Joseph· Chief Executive Officer | Option exercise | 1,266,903 | — | — | filing |
| 2026-06-11 | Heidbreder Christian· Chief Scientific Officer | Sale | 18,586 | $38.06 | $707,383.16 | filing |
| 2026-06-08 | Preblick Ryan· Chief Financial Officer | Sale | 36,000 | $37.70 | $1.4M | filing |
| 2026-05-13 | Stejbach Mark | Award | 6,518 | $0.00 | $0.00 | filing |
| 2026-05-13 | Wheadon David E. | Award | 10,430 | $0.00 | $0.00 | filing |
| 2026-05-13 | Humphreys Keith | Award | 6,518 | $0.00 | $0.00 | filing |
| 2026-05-13 | Thompson Juliet | Award | 6,518 | $0.00 | $0.00 | filing |
| 2026-05-13 | Kingsley Stuart A | Award | 6,518 | $0.00 | $0.00 | filing |
| 2026-05-13 | NINIVAGGI DANIEL A | Award | 6,518 | $0.00 | $0.00 | filing |
| 2026-05-13 | Ryan Barbara | Award | 6,518 | $0.00 | $0.00 | filing |
| 2026-05-12 | Thompson Juliet | Tax withholding | 1,117 | $38.28 | $42,758.76 | filing |
| 2026-03-14 | Preblick Ryan· Chief Financial Officer | Tax withholding | 2,843 | $31.11 | $88,445.73 | filing |
| 2026-03-14 | Preblick Ryan· Chief Financial Officer | Option exercise | 6,302 | — | — | filing |
| 2026-03-13 | Ryan Barbara | Buy | 8 | $31.09 | $248.68 | filing |
| 2026-03-09 | Ryan Barbara | Buy | 31 | $32.56 | $1,009.36 | filing |
| 2026-03-06 | Kingsley Stuart A | Buy | 940 | $31.87 | $29,953.10 | filing |
| 2026-03-03 | Preblick Ryan· Chief Financial Officer | Tax withholding | 87,597 | $31.98 | $2.8M | filing |
| 2026-03-03 | Heidbreder Christian· Chief Scientific Officer | Tax withholding | 45,797 | $31.98 | $1.5M | filing |
| 2026-03-03 | Burris Jeffrey W· Chief Legal Officer | Tax withholding | 36,032 | $31.98 | $1.2M | filing |
| 2026-03-03 | Anderson Woodrow D· Chief Accounting Officer | Tax withholding | 8,283 | $31.98 | $264,890.34 | filing |
| 2026-03-03 | Anderson Woodrow D· Chief Accounting Officer | Tax withholding | 2,682 | $31.98 | $85,770.36 | filing |
| 2026-03-03 | Heidbreder Christian· Chief Scientific Officer | Option exercise | 101,544 | — | — | filing |
| 2026-03-03 | Anderson Woodrow D· Chief Accounting Officer | Option exercise | 5,946 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.